Posted On: 11/09/2016 8:23:28 AM
Post# of 72447
Prurisol: "Benefits were apparent by two weeks and showed further improvement by the end of the study at 12 weeks.
Cellceutix has commenced a randomized, double-blind, parallel-group, placebo-controlled Phase 2b trial of Prurisol for approximately 189 subjects with moderate to severe plaque psoriasis. Daily Prurisol dosage has been increased from 200mg. The treatment group arms are Prurisol 300mg, Placebo, Prurisol 400mg (Ratio 3:3:1) with a treatment duration of 12 weeks.
The Company expects interim analysis top-line results in the second quarter of calendar 2017. "
Cellceutix has commenced a randomized, double-blind, parallel-group, placebo-controlled Phase 2b trial of Prurisol for approximately 189 subjects with moderate to severe plaque psoriasis. Daily Prurisol dosage has been increased from 200mg. The treatment group arms are Prurisol 300mg, Placebo, Prurisol 400mg (Ratio 3:3:1) with a treatment duration of 12 weeks.
The Company expects interim analysis top-line results in the second quarter of calendar 2017. "
(1)
(0)
